Search for "sugars" in Full Text gives 196 result(s) in Beilstein Journal of Organic Chemistry.
Beilstein J. Org. Chem. 2011, 7, 897–936, doi:10.3762/bjoc.7.103
Graphical Abstract
Scheme 1: Gold-catalyzed addition of alcohols.
Scheme 2: Gold-catalyzed cycloaddition of alcohols.
Scheme 3: Ionic liquids as the solvent in gold-catalyzed cycloaddition.
Scheme 4: Gold-catalyzed cycloaddition of diynes.
Scheme 5: Gold(I) chloride catalyzed cycloisomerization of 2-alkynyl-1,5-diols.
Scheme 6: Gold-catalyzed cycloaddition of glycols and dihydroxy compounds.
Scheme 7: Gold-catalyzed ring-opening of cyclopropenes.
Scheme 8: Gold-catalyzed intermolecular hydroalkoxylation of alkynes. PR3 = 41–45.
Scheme 9: Gold-catalyzed intramolecular 6-endo-dig cyclization of β-hydroxy-α,α-difluoroynones.
Scheme 10: Gold-catalyzed intermolecular hydroalkoxylation of non-activated olefins.
Scheme 11: Preparation of unsymmetrical ethers from alcohols.
Scheme 12: Expedient synthesis of dihydrofuran-3-ones.
Scheme 13: Catalytic approach to functionalized divinyl ketones.
Scheme 14: Gold-catalyzed glycosylation.
Scheme 15: Gold-catalyzed cycloaddition of aldehydes and ketones.
Scheme 16: Gold-catalyzed annulations of 2-(ynol)aryl aldehydes and o-alkynyl benzaldehydes.
Scheme 17: Gold-catalyzed addition of carboxylates.
Scheme 18: Dual-catalyzed rearrangement reaction of allenoates.
Scheme 19: Meyer–Schuster rearrangement of propargylic alcohols.
Scheme 20: Propargylic alcohol rearrangements.
Scheme 21: Gold-catalyzed synthesis of imines and amine alkylation.
Scheme 22: Hydroamination of allenes and allenamides.
Scheme 23: Gold-catalyzed inter- and intramolecular amination of alkynes and alkenes.
Scheme 24: Gold-catalyzed cycloisomerization of O-propioloyl oximes and β-allenylhydrazones.
Scheme 25: Intra- and intermolecular amination with ureas.
Scheme 26: Gold-catalyzed cyclization of ortho-alkynyl-N-sulfonylanilines and but-3-yn-1-amines.
Scheme 27: Gold-catalyzed piperidine ring synthesis.
Scheme 28: Ring expansion of alkylnyl cyclopropanes.
Scheme 29: Gold-catalyzed annulations of N-propargyl-β-enaminones and azomethine imines.
Scheme 30: Gold(I)-catalyzed cycloisomerization of aziridines.
Scheme 31: AuCl3/AgSbF6-catalyzed intramolecular amination of 2-(tosylamino)phenylprop-1-en-3-ols.
Scheme 32: Gold-catalyzed cyclization via a 7-endo-dig pathway.
Scheme 33: Gold-catalyzed synthesis of fused xanthines.
Scheme 34: Gold-catalyzed synthesis of amides and isoquinolines.
Scheme 35: Gold-catalyzed oxidative cross-coupling reactions of propargylic acetates.
Scheme 36: Gold-catalyzed nucleophilic addition to allenamides.
Scheme 37: Gold-catalyzed direct carbon–carbon bond coupling reactions.
Scheme 38: Gold-catalyzed C−H functionalization of indole/pyrrole heterocycles and non-activated arenes.
Scheme 39: Gold-catalyzed cycloisomerization of cyclic compounds.
Scheme 40: Gold-catalyzed cycloaddition of 1-aryl-1-allen-6-enes and propargyl acetates.
Scheme 41: Gold(I)-catalyzed cycloaddition with ligand-controlled regiochemistry.
Scheme 42: Gold(I)-catalyzed cycloaddition of dienes and enynes.
Scheme 43: Gold-catalyzed intramolecular cycloaddition of 3-alkoxy-1,5-enynes and 2,2-dipropargylmalonates.
Scheme 44: Gold-catalyzed intramolecular cycloaddition of 1,5-allenynes.
Scheme 45: Gold(I)-catalyzed cycloaddition of indoles.
Scheme 46: Gold-catalyzed annulation reactions.
Scheme 47: Gold–carbenoid induced cleavage of a sp3-hybridized C−H bond.
Scheme 48: Furan- and indole-based cascade reactions.
Scheme 49: Tandem process using aromatic alkynes.
Scheme 50: Gold-catalyzed cycloaddition of 1,3-dien-5-ynes.
Scheme 51: Gold-catalyzed cascade cyclization of diynes, propargylic esters, and 1,3-enynyl ketones.
Scheme 52: Tandem reaction of β-phenoxyimino ketones and alkynyl oxime ethers.
Scheme 53: Gold-catalyzed tandem cyclization of enynes, 2-(tosylamino)phenylprop-1-yn-3-ols, and allenoates.
Scheme 54: Cyclization of 2,4-dien-6-yne carboxylic acids.
Scheme 55: Gold(I)-catalyzed tandem cyclization approach to tetracyclic indolines.
Scheme 56: Gold-catalyzed tandem reactions of alkynes.
Scheme 57: Aminoarylation and oxyarylation of alkenes.
Scheme 58: Cycloaddition of 2-ethynylnitrobenzene with various alkenes.
Scheme 59: Gold-catalyzed tandem reactions of allenoates and alkynes.
Scheme 60: Gold-catalyzed asymmetric synthesis of 2,3-dihydropyrroles.
Scheme 61: Chiral [NHC–Au(I)]-catalyzed cyclization of enyne.
Scheme 62: Gold-catalyzed hydroaminations and hydroalkoxylations.
Scheme 63: Gold(I)-catalyzed asymmetric hydroalkoxylation of 1,3-dihydroxymethyl-2-alkynylbenzene chromium com...
Scheme 64: Gold-catalyzed synthesis of julolidine derivatives.
Scheme 65: Gold-catalyzed the synthesis of chiral fused heterocycles.
Scheme 66: Gold-catalyzed asymmetric reactions with 3,5-(t-Bu)2-4-MeO-MeOBIPHEP.
Scheme 67: Gold-catalyzed cyclization of o-(alkynyl) styrenes.
Scheme 68: Asymmetric gold(I)-catalyzed redox-neutral domino reactions of enynes.
Scheme 69: Gold(I)-catalyzed enantioselective polyene cyclization reaction.
Scheme 70: Gold(I)-catalyzed enantioselective synthesis of benzopyrans.
Scheme 71: Gold(I)-catalyzed enantioselective ring expansion of allenylcyclopropanols.
Beilstein J. Org. Chem. 2011, 7, 699–716, doi:10.3762/bjoc.7.81
Graphical Abstract
Scheme 1: Well-defined Mo- and Ru-alkylidene metathesis catalysts.
Scheme 2: Representative pyrrolidine-based iminocyclitols.
Scheme 3: Synthesis of (±)-(2R*,3R*,4S*)-2-hydroxymethylpyrrolidin-3,4-diol (18), (±)-2-hydroxymethylpyrrolid...
Scheme 4: Synthesis of enantiopure iminocyclitol (−)-(2S,3R,4S,5S)-2,5-dihydroxymethylpyrrolidin-3,4-diol (23...
Scheme 5: Synthesis of 1,4-dideoxy-1,4-imino-D-allitol (29) and formal synthesis of (2S,3R,4S)-3,4-dihydroxyp...
Scheme 6: Synthesis of iminocyclitols 35 and 36.
Scheme 7: Total synthesis of iminocyclitols 40 and 44.
Scheme 8: Synthesis of 2,5-dideoxy-2,5-imino-D-mannitol [(+)-DMDP] (49) and (−)-bulgecinine (50).
Scheme 9: Synthesis of (+)-broussonetine G (53).
Scheme 10: Structural features of broussonetines 54.
Scheme 11: Synthesis of broussonetines by cross-metathesis.
Scheme 12: Representative piperidine-based iminocyclitols.
Scheme 13: Total synthesis of 1-deoxynojirimycin (62) and 1-deoxyaltronojirimycin (65).
Scheme 14: Synthesis by RCM of 1-deoxymannonojirimycin (63) and 1-deoxyallonojirimycin (66).
Scheme 15: Total synthesis of (+)-1-deoxynojirimycin (62).
Scheme 16: Synthesis of ent-1,6-dideoxynojirimycin (83) and 5-amino-1,5,6-trideoxyaltrose (84).
Scheme 17: Synthesis of 1-deoxygalactonojirimycin (64), 1-deoxygulonojirimycin (91) and 1-deoxyidonojirimycin (...
Scheme 18: Synthesis of L-1-deoxyaltronojirimycin (96).
Scheme 19: Synthesis of 1-deoxymannonojirimycin (63) and 1-deoxyaltronojirimycin (65).
Scheme 20: Synthesis of 5-des(hydroxymethyl)-1-deoxymannonojirimycin (111) and 5-des(hydroxymethyl)-1-deoxynoj...
Scheme 21: Synthesis of D-1-deoxygulonojirimycin (91) and L-1-deoxyallonojirimycin (122).
Scheme 22: Total synthesis of fagomine (129), 3-epi-fagomine (126) and 3,4-di-epi-fagomine (130).
Scheme 23: Total synthesis of (+)-adenophorine (135).
Scheme 24: Total synthesis of (+)-5-deoxyadenophorine (138) and analogues 142–145.
Scheme 25: Synthesis by RCM of 1,6-dideoxy-1,6-iminoheptitols 148 and 149.
Scheme 26: Synthesis by RCM of oxazolidinyl azacycles 152 and 154.
Scheme 27: Representative azepane-based iminocyclitols.
Scheme 28: Synthesis of hydroxymethyl-1-(4-methylphenylsulfonyl)azepane 3,4,5-triol (169).
Scheme 29: Synthesis by RCM of tetrahydropyridin-3-ol 171 and tetrahydroazepin-3-ol 173.
Beilstein J. Org. Chem. 2011, 7, 369–377, doi:10.3762/bjoc.7.47
Graphical Abstract
Scheme 1: Indicative topology model for the biosynthesis of the glycophospholipids PIMs, LM and LAM in mycoba...
Figure 1: Chemical structures of (A) a representative PIM, AcPIM5 and (B) a mannan fragment of LM from mycoba...
Figure 2: Target di- and trisaccharide glycoconjugate fragments of PIMs and LM.
Scheme 2: Synthesis of azidooctyl alcohol 14 and diol 15.
Scheme 3: Synthesis of mannosyl donors 16 and 17.
Figure 3: ORTEP plot of single crystal X-ray determination of (7S)-18. Thermal ellipsoids denote 20% electron...
Scheme 4: Synthesis of disaccharide 1 and trisaccharide 2.
Scheme 5: Synthesis of trisaccharide 3.
Scheme 6: Synthesis of trisaccharide 4.
Scheme 7: Synthesis of glycoconjugates 5–7 and 8–10.
Beilstein J. Org. Chem. 2010, 6, 699–703, doi:10.3762/bjoc.6.81
Graphical Abstract
Figure 1: Aminoethyl glycosides (1–9) which were synthesised in this study.
Scheme 1: General reaction scheme for generation of aminoethyl glycosides. X = OAc, Br or Cl.
Scheme 2: Deprotection protocols.
Beilstein J. Org. Chem. 2010, 6, No. 75, doi:10.3762/bjoc.6.75
Graphical Abstract
Scheme 1: Synthesis of 3,6-dihydro-2H-pyrans D.
Scheme 2: Addition of lithiated enol ether 1a to nitrone 2c/Et2AlCl.
Scheme 3: Mechanistic proposal for the transformation of syn-4a into cis-5a in the presence of TMSOTf.
Scheme 4: Unsuccessful attempt to cyclize hydroxylamine derivative syn-4f.
Scheme 5: Functionalizations of the enol ether moiety of cis-5a leading to compounds 8–11.
Scheme 6: Transformations of the enol ether moiety of trans-5a leading to products 13–15.
Scheme 7: Bromination of bicyclic dihydropyran trans-5b affording 16.
Scheme 8: Synthesis of epoxypyran 18 by bromination of cis-5d.
Scheme 9: Oxidative cleavage of dihydropyran 19 to lactone 20.
Scheme 10: Transformation of α-bromoketone 15 into nitrone 21 by an internal redox reaction.
Scheme 11: Transformation of α-bromoketone 11 into nitrone 21.
Scheme 12: Synthesis of diastereomeric aminopyrans 24 and 26.
Scheme 13: Synthesis of diastereomeric aminopyrans 28 and 30.
Scheme 14: Synthesis of triamides 31 and 32.
Beilstein J. Org. Chem. 2010, 6, No. 58, doi:10.3762/bjoc.6.58
Graphical Abstract
Figure 1: Preparation of the 8-azido-3,6-dioxaoctyl α-D-mannopyranoside.
Figure 2: Preparation of poly(propargyl-co-N-vinyl pyrrolidone) and subsequent addition of the mannose deriva...
Figure 3: Size of the nanoparticles stabilized with Pluronic® F-68/NVP-PA-Man (0.8/0.2), after addition of in...
Figure 4: Hydrogen and carbon numbering for NMR assignment.
Beilstein J. Org. Chem. 2010, 6, No. 47, doi:10.3762/bjoc.6.47
Graphical Abstract
Figure 1: Structures of the naturally occurring TN and TF antigens and the targeted Fmoc-β3hThr analogues.
Scheme 1: Synthesis of Fmoc-β3hThr antigen conjugates by Arndt–Eistert homologation.
Scheme 2: Solid-phase synthesis of the tumour-associated MUC1 α/β-hybrid glycopeptide analogue 8 carrying the...
Beilstein J. Org. Chem. 2010, 6, No. 32, doi:10.3762/bjoc.6.32
Graphical Abstract
Figure 1: Biologically important amines and quaternary ammonium salts: histamine (1), dopamine (2) and acetyl...
Figure 2: Crown ether 18-crown-6.
Figure 3: Conformations of 18-crown-6 (4) in solvents of different polarity.
Figure 4: Binding topologies of the ammonium ion depending on the crown ring size.
Figure 5: A “pseudorotaxane” structure consisting of 24-crown-8 and a secondary ammonium ion (5); R = Ph.
Figure 6: Typical examples of azacrown ethers, cryptands and related aza macrocycles.
Figure 7: Binding of ammonium to azacrown ethers and cryptands [111-113].
Figure 8: A 19-crown-6-ether with decalino blocking groups (11) and a thiazole-dibenzo-18-crown-6-ether (12).
Figure 9: 1,3-Bis(6-oxopyridazin-1-yl)propane derivatives 13 and 14 by Campayo et al.
Figure 10: Fluorescent azacrown-PET-sensors based on coumarin.
Figure 11: Two different pyridino-cryptands (17 and 18) compared to a pyridino-crown (19); chiral ammonium ion...
Figure 12: Pyridino-18-crown-6 ligand (21), a similar acridino-18-crown-6 ligand (22) and a structurally relat...
Figure 13: Ciral pyridine-azacrown ether receptors 24.
Figure 14: Chiral 15-crown-5 receptors 26 and an analogue 18-crown-6 ligand 27 derived from amino alcohols.
Figure 15: C2-symmetric chiral 18-crown-6 amino alcohol derivatives 28 and related macrocycles.
Figure 16: Macrocycles with diamide-diester groups (30).
Figure 17: C2-symmetric chiral aza-18-crown-6 ethers (31) with phenethylamine residues.
Figure 18: Chiral C-pivot p-methoxy-phenoxy-lariat ethers.
Figure 19: Chiral lariat crown ether 34.
Figure 20: Sucrose-based chiral crown ether receptors 36.
Figure 21: Permethylated fructooligosaccharide 37 showing induced-fit chiral recognition.
Figure 22: Biphenanthryl-18-crown-6 derivative 38.
Figure 23: Chiral lariat crown ethers derived from binol by Fuji et al.
Figure 24: Chiral phenolic crown ether 41 with “aryl chiral barriers” and guest amines.
Figure 25: Chiral bis-crown receptor 43 with a meso-ternaphthalene backbone.
Figure 26: Chromogenic pH-dependent bis-crown chemosensor 44 for diamines.
Figure 27: Triamine guests for binding to receptor 44.
Figure 28: Chiral bis-crown phenolphthalein chemosensors 46.
Figure 29: Crown ether amino acid 47.
Figure 30: Luminescent receptor 48 for bis-alkylammonium guests.
Figure 31: Luminescent CEAA (49a), a bis-CEAA receptor for amino acids (49b) and the structure of lysine bindi...
Figure 32: Luminescent CEAA tripeptide for binding small peptides.
Figure 33: Bis crown ether 51a self assembles co-operatively with C60-ammonium ion 51b.
Figure 34: Triptycene-based macrotricyclic dibenzo-[24]-crown-8 ether host 52 and guests.
Figure 35: Copper imido diacetic acid azacrown receptor 53a and the suggested His-Lys binding motif; a copper ...
Figure 36: Urea (54) and thiourea (55) benzo crown receptor for transport and extraction of amino acids.
Figure 37: Crown pyryliums ion receptors 56 for amino acids.
Figure 38: Ditopic sulfonamide bridged crown ether receptor 57.
Figure 39: Luminescent peptide receptor 58.
Figure 40: Luminescent receptor 59 for the detection of D-glucosamine hydrochloride in water/ethanol and lumin...
Figure 41: Guanidinium azacrown receptor 61 for simple amino acids and ditopic receptor 62 with crown ether an...
Figure 42: Chiral bicyclic guanidinium azacrown receptor 63 and similar receptor 64 for the enantioselective t...
Figure 43: Receptors for zwitterionic species based on luminescent CEAAs.
Figure 44: 1,10-Azacrown ethers with sugar podand arms and the anticancer agent busulfan.
Figure 45: Benzo-18-crown-6 modified β-cyclodextrin 69 and β-cyclodextrin functionalized with diaza-18-crown-6...
Figure 46: Receptors for colorimetric detection of primary and secondary ammonium ions.
Figure 47: Porphyrine-crown-receptors 72.
Figure 48: Porphyrin-crown ether conjugate 73 and fullerene-ammonium ion guest 74.
Figure 49: Calix[4]arene (75a), homooxocalix[4]arene (75b) and resorcin[4]arene (75c) compared (R = H, alkyl c...
Figure 50: Calix[4]arene and ammonium ion guest (R = H, alkyl, OAcyl etc.), possible binding sites; A: co-ordi...
Figure 51: Typical guests for studies with calixarenes and related molecules.
Figure 52: Lower rim modified p-tert-butylcalix[5]arenes 82.
Figure 53: The first example of a water soluble calixarene.
Figure 54: Sulfonated water soluble calix[n]arenes that bind ammonium ions.
Figure 55: Displacement assay for acetylcholine (3) with a sulfonato-calix[6]arene (84b).
Figure 56: Amino acid inclusion in p-sulfonatocalix[4]arene (84a).
Figure 57: Calixarene receptor family 86 with upper and lower rim functionalization.
Figure 58: Calix[6]arenes 87 with one carboxylic acid functionality.
Figure 59: Sulfonated calix[n]arenes with mono-substitution at the lower rim systematically studied on their r...
Figure 60: Cyclotetrachromotropylene host (91) and its binding to lysine (81c).
Figure 61: Calixarenes 92 and 93 with phosphonic acids groups.
Figure 62: Calix[4]arene tetraphosphonic acid (94a) and a double bridged analogue (94b).
Figure 63: Calix[4]arene tetraphosphonic acid ester (92c) for surface recognition experiments.
Figure 64: Calixarene receptors 95 with α-aminophosphonate groups.
Figure 65: A bridged homocalix[3]arene 95 and a distally bridged homocalix[4]crown 96.
Figure 66: Homocalix[3]arene ammonium ion receptor 97a and the Reichardt’s dye (97b) for colorimetric assays.
Figure 67: Chromogenic diazo-bridged calix[4]arene 98.
Figure 68: Calixarene receptor 99 by Huang et al.
Figure 69: Calixarenes 100 reported by Parisi et al.
Figure 70: Guest molecules for inclusion in calixarenes 100: DAP × 2 HCl (101a), APA (101b) and Lys-OMe × 2 HC...
Figure 71: Different N-linked peptido-calixarenes open and with glycol chain bridges.
Figure 72: (S)-1,1′-Bi-2-naphthol calixarene derivative 104 published by Kubo et al.
Figure 73: A chiral ammonium-ion receptor 105 based on the calix[4]arene skeleton.
Figure 74: R-/S-phenylalaninol functionalized calix[6]arenes 106a and 106b.
Figure 75: Capped homocalix[3]arene ammonium ion receptor 107.
Figure 76: Two C3 symmetric capped calix[6]arenes 108 and 109.
Figure 77: Phosphorous-containing rigidified calix[6]arene 110.
Figure 78: Calix[6]azacryptand 111.
Figure 79: Further substituted calix[6]azacryptands 112.
Figure 80: Resorcin[4]arene (75c) and the cavitands (113).
Figure 81: Tetrasulfonatomethylcalix[4]resorcinarene (114).
Figure 82: Resorcin[4]arenes (115a/b) and pyrogallo[4]arenes (115c, 116).
Figure 83: Displacement assay for acetylcholine (3) with tetracyanoresorcin[4]arene (117).
Figure 84: Tetramethoxy resorcinarene mono-crown-5 (118).
Figure 85: Components of a resorcinarene based displacement assay for ammonium ions.
Figure 86: Chiral basket resorcin[4]arenas 121.
Figure 87: Resorcinarenes with deeper cavitand structure (122).
Figure 88: Resorcinarene with partially open deeper cavitand structure (123).
Figure 89: Water-stabilized deep cavitands with partially structure (124, 125).
Figure 90: Charged cavitands 126 for tetralkylammonium ions.
Figure 91: Ditopic calix[4]arene receptor 127 capped with glycol chains.
Figure 92: A calix[5]arene dimer for diammonium salt recognition.
Figure 93: Calixarene parts 92c and 129 for the formation molecular capsules.
Figure 94: Encapsulation of a quaternary ammonium cation by two resorcin[4]arene molecules (NMe4+@[75c]2 × Cl−...
Figure 95: Encapsulation of a quaternary ammonium cation by six resorcin[4]arene molecules (NMe3D+@[130]6 × Cl−...
Figure 96: Structure and schematic of cucurbit[6]uril (CB[6], 131a).
Figure 97: Cyclohexanocucurbit[6]uril (CB′[6], 132) and the guest molecule spermine (133).
Figure 98: α,α,δ,δ-Tetramethylcucurbit[6]uril (134).
Figure 99: Structure of the cucurbituril-phthalhydrazide analogue 135.
Figure 100: Organic cavities for the displacement assay for amine differentiation.
Figure 101: Displacement assay methodology for diammonium- and related guests involving cucurbiturils and some ...
Figure 102: Nor-seco-Cucurbituril (±)-bis-ns-CB[6] (140) and guest molecules.
Figure 103: The cucurbit[6]uril based complexes 141 for chiral discrimination.
Figure 104: Cucurbit[7]uril (131c) and its ferrocene guests (142) opposed.
Figure 105: Cucurbit[7]uril (131c) guest inclusion and representative guests.
Figure 106: Cucurbit[7]uril (131c) binding to succinylcholine (145) and different bis-ammonium and bis-phosphon...
Figure 107: Paraquat-cucurbit[8]uril complex 149.
Figure 108: Gluconuril-based ammonium receptors 150.
Figure 109: Examples of clefts (151a), tweezers (151b, 151c, 151d) and clips (151e).
Figure 110: Kemp’s triacid (152a), on example of Rebek’s receptors (152b) and guests.
Figure 111: Amino acid receptor (154) by Rebek et al.
Figure 112: Hexagonal lattice designed hosts by Bell et al.
Figure 113: Bell’s amidinium receptor (156) and the amidinium ion (157).
Figure 114: Aromatic phosphonic acids.
Figure 115: Xylene phosphonates 159 and 160a/b for recognition of amines and amino alcohols.
Figure 116: Bisphosphonate recognition motif 161 for a colorimetric assay with alizarin complexone (163) for ca...
Figure 117: Bisphosphonate/phosphate clip 164 and bisphosphonate cleft 165.
Figure 118: N-Methylpyrazine 166a, N-methylnicotinamide iodide (166b) and NAD+ (166c).
Figure 119: Bisphosphate cavitands.
Figure 120: Bisphosphonate 167 of Schrader and Finocchiaro.
Figure 121: Tweezer 168 for noradrenaline (80b).
Figure 122: Different tripods and heparin (170).
Figure 123: Squaramide based receptors 172.
Figure 124: Cage like NH4+ receptor 173 of Kim et al.
Figure 125: Ammonium receptors 174 of Chin et al.
Figure 126: 2-Oxazolin-based ammonium receptors 175a–d and 176 by Ahn et al.
Figure 127: Racemic guest molecules 177.
Figure 128: Tripods based on a imidazole containing macrocycle (178) and the guest molecules employed in the st...
Figure 129: Ammonium ion receptor 180.
Figure 130: Tetraoxa[3.3.3.3]paracyclophanes 181 and a cyclophanic tetraester (182).
Figure 131: Peptidic bridged paraquat-cyclophane.
Figure 132: Shape-selective noradrenaline host.
Figure 133: Receptor 185 for binding of noradrenaline on surface layers from Schrader et al.
Figure 134: Tetraphosphonate receptor for binding of noradrenaline.
Figure 135: Tetraphosphonate 187 of Schrader and Finocchiaro.
Figure 136: Zinc-Porphyrin ammonium-ion receptors 188 and 189 of Mizutani et al.
Figure 137: Zinc porphyrin receptor 190.
Figure 138: Zinc porphyrin receptors 191 capable of amino acid binding.
Figure 139: Zinc-porphyrins with amino acid side chains for stereoinduction.
Figure 140: Bis-zinc-bis-porphyrin based on Tröger’s base 193.
Figure 141: BINAP-zinc-prophyrin derivative 194 and it’s guests.
Figure 142: Bisaryl-linked-zinc-porphyrin receptors.
Figure 143: Bis-zinc-porphyrin 199 for diamine recognition and guests.
Figure 144: Bis-zinc-porphyrin crown ether 201.
Figure 145: Bis-zinc-porphyrin 202 for stereodiscrimination (L = large substituent; S = small substituent).
Figure 146: Bis-zinc-porphyrin[3]rotaxane and its copper complex and guests.
Figure 147: Dien-bipyridyl ligand 206 for co-ordination of two metal atoms.
Figure 148: The ligand and corresponding tetradentate co-complex 207 serving as enantioselective receptor for a...
Figure 149: Bis(oxazoline)–copper(II) complex 208 for the recognition of amino acids in aqueous solution.
Figure 150: Zinc-salen-complexes 209 for the recognition tertiary amines.
Figure 151: Bis(oxazoline)–copper(II) 211 for the recognition of amino acids in aqueous solution.
Figure 152: Zn(II)-complex of a C2 terpyridine crown ether.
Figure 153: Displacement assay and receptor for aspartate over glutamate.
Figure 154: Chiral complex 214 for a colorimetric displacement assay for amino acids.
Figure 155: Metal complex receptor 215 with tripeptide side arms.
Figure 156: A sandwich complex 216 and its displaceable dye 217.
Figure 157: Lanthanide complexes 218–220 for amino acid recognition.
Figure 158: Nonactin (221), valinomycin (222) and vancomycin (223).
Figure 159: Monesin (224a) and a chiral analogue for enantiodiscrimination of ammonium guests (224b).
Figure 160: Chiral podands (226) compared to pentaglyme-dimethylether (225) and 18-crown-6 (4).
Figure 161: Lasalocid A (228).
Figure 162: Lasalocid derivatives (230) of Sessler et al.
Figure 163: The Coporphyrin I tetraanion (231).
Figure 164: Linear and cyclic peptides for ammonium ion recognition.
Figure 165: Cyclic and bicyclic depsipeptides for ammonium ion recognition.
Figure 166: α-Cyclodextrin (136a) and novocaine (236).
Figure 167: Helical diol receptor 237 by Reetz and Sostmann.
Figure 168: Ammonium binding spherand by Cram et al. (238a) and the cyclic[6]metaphenylacetylene 238b in compar...
Figure 169: Receptor for peptide backbone and ammonium binding (239).
Figure 170: Anion sensor principle with 3-hydroxy-2-naphthanilide of Jiang et al.
Figure 171: 7-bromo-3-hydroxy-N-(2-hydroxyphenyl)naphthalene 2-carboxamide (241) and its amine binding.
Figure 172: Naturally occurring catechins with affinity to quaternary ammonium ions.
Figure 173: Spiropyran (244) and merocyanine form (244a) of the amino acid receptors of Fuji et al.
Figure 174: Coumarin aldehyde (245) and its iminium species with amino acid bound (245a) by Glass et al.
Figure 175: Coumarin aldehyde appended with boronic acid.
Figure 176: Quinolone aldehyde dimers by Glass et al.
Figure 177: Chromogenic ammonium ion receptors with trifluoroacetophenone recognition motifs.
Figure 178: Chromogenic ammonium ion receptor with trifluoroacetophenone recognition motif bound on different m...
Beilstein J. Org. Chem. 2010, 6, No. 24, doi:10.3762/bjoc.6.24
Graphical Abstract
Scheme 1: The natural forms of sialic acids, human N-acetylneuraminic acid (Neu5Ac, 1) and mammalian N-glycol...
Scheme 2: Synthesis of N-(1-oxohex-5-ynyl)neuraminic acid (Neu5Hex 3).
Scheme 3: Metabolic pathway of Ac4GlcNAz and the genetic control of Neu5Ac 1 synthesis by feedback inhibition...
Scheme 4: Proposed metabolic pathway of Neu5Hex 3 based on known mechanisms of Neu5Gc 2 uptake [5]. TGN: trans-G...
Scheme 5: Labelling of alkynylated neuraminic acid by azido-fluorescein.
Figure 1: Top left: HEp-2 cells incorporated with Ac4GlcNAz 16, labelled with alkynylated TAMRA at 580 nm. Bo...
Beilstein J. Org. Chem. 2010, 6, No. 20, doi:10.3762/bjoc.6.20
Graphical Abstract
Figure 1: Schematic representation of sugar aminoacids (SAAs) and (pseudo)amide oligosaccharide mimetics.
Figure 2: Natural SAAs structures and natural nucleosidic antibiotics.
Scheme 1: Synthetic route to the target amide-linked sialooligomers. (a) Fmoc-Cl, NaHCO3, H2O, dioxane, 0 °C....
Figure 3: The general structure of glycoamino acids and their corresponding oligomers.
Figure 4: Conformational analysis of the β(1→2)-amide-linked glucooligomer 9.
Figure 5: Short oligomeric chains of C-glycosyl D-arabino THF amino acid oligomers.
Figure 6: (A) Stereoview of the minimized structure of compound 16 (produced by a 500 ps simulation) that mos...
Figure 7: Structures of linear oxetane-β- and δ-SAA homo-oligomers 19–20.
Figure 8: 10-Membered ring H-bonds in compound 21 consistent with NMR and modelling investigations.
Figure 9: General structure of carbopeptoid-oligonucleotide conjugates.
Figure 10: Protected derivatives of 2,6-diamino-2,6-dideoxy-β-D-glucopyranosyl carboxylic acid 22 and 23.
Figure 11: Cyclic homo-oligomers containing glucopyranoid-SAAs.
Scheme 2: Strategy for solid-phase synthesis of cyclic trimers and tetramers containing pyranoid δ-SAAs.
Figure 12: Cyclic tetramers of L-rhamno- and D-gulo-configured oxetane-SAAs.
Figure 13: Aminoglycosidic antibiotics of the glycocinnamoylspermidine family.
Scheme 3: Synthesis of (thio)trehazoline, via triflate, from β-hydroxy(thio)urea.
Figure 14: Approaches to access pseudoamide-type oligosaccharide mimics.
Figure 15: Calystegine B2 analogues 38 and 39 with urea-linked disaccharide structure.
Figure 16: Rotameric equilibrium shift of 40 by formation of a bidentate hydrogen bond.
Figure 17: Nucleotide analogues with thiourea and S-methylisothiouronium linkers.
Scheme 4: Retrosynthetic approach to synthesize thiourea-linked glycooligomers.
Figure 18: Rotameric equilibria for β-(1→6)-thiourea-linked glucodimer 41.
Figure 19: Schematic representation of (a) cyclodextrin (CDs) and (b) cyclotrehalan (CTs) family members.
Scheme 5: Synthesis of guanidine-linked pseudodisaccharides via carbodiimide.
Figure 20: β(1→6)-Guanidine-linked pseudodi- and pseudotrisaccharides 47 and 48.
Scheme 6: Synthesis of N-benzylguanidine-linked CT2 50.
Figure 21: Structure of RNG and DNG.
Figure 22: Preparation of Fmoc-guanidinium derivatives.
Figure 23: Structures of the homo-oligomeric RNG derivatives 51–55.
Figure 24: Phosphoramidite building block 56.
Figure 25: Structures of DNGs 57–65.
Figure 26: Structure of the phosphoramidite building block 66.
Beilstein J. Org. Chem. 2010, 6, No. 16, doi:10.3762/bjoc.6.16
Beilstein J. Org. Chem. 2010, 6, No. 15, doi:10.3762/bjoc.6.15
Graphical Abstract
Scheme 1: Synthesis of bis-carbamate 12 and oxazolidinone 13.
Scheme 2: Mechanism of the palladium-catalyzed ionization/cyclization reaction.
Scheme 3: Synthesis of aminocyclitol analogue 6.
Figure 1: The thermal ellipsoid plot of the single crystal X-ray crystallographic structure of 18.
Scheme 4: Synthesis of oxazolidone 23.
Scheme 5: Mechanism of the palladium-catalyzed ionization/cyclization reaction in dichloro biscarbamate 22.
Scheme 6: Synthesis of dichloroaminocyclitol 7.
Figure 2: 1H NMR NOE spectrum of compound 7.
Beilstein J. Org. Chem. 2010, 6, No. 9, doi:10.3762/bjoc.6.9
Graphical Abstract
Figure 1: Examples of hydrogen bonds in the complex of a) galactose-binding protein with D-glucose [3], b) Amara...
Figure 2: Structures of receptors 1–5.
Figure 3: Structures of sugars investigated in this study.
Scheme 1: Reaction conditions: a) AlCl3, CH3CH2Br, 0 °C to r. t., 12 h (85%) [47]; b) 33% HBr in CH3COOH, ZnBr2, ...
Figure 4: Structures of the recently described phenanthroline/aminopyridine-based receptors showing α- vs. β-...
Figure 5: Partial 1H NMR spectra (400 MHz; CDCl3) of receptor 4 (a), 5 (b), 1 (c), and 3 (d) before (bottom) ...
Figure 6: Partial 1H NMR spectra (400 MHz, CDCl3) of 5 after addition of (from bottom to top) 0.00–1.63 equiv...
Figure 7: Energy-minimized structure of the 1:1 a) and 2:1 complex b) formed between receptor 4 and β-galacto...
Figure 8: Examples of hydrogen bonding motifs indicated by molecular modeling studies in the 1:1 complex betw...
Beilstein J. Org. Chem. 2009, 5, No. 40, doi:10.3762/bjoc.5.40
Graphical Abstract
Figure 1: Synthetic strategy for asparagine-linked oligosaccharide on solid support and application of microf...
Figure 2: β-Mannosylation using an integrated microfluidic/batch system. Yield and β/α-ratio are analyzed by 1...
Scheme 1: Synthesis of pristane.
Figure 3: Process synthesis of pristane via microfluidic dehydration as a key step.
Scheme 2: Microfluidic dehydration.
Beilstein J. Org. Chem. 2008, 4, No. 48, doi:10.3762/bjoc.4.48
Graphical Abstract
Scheme 1: Total synthesis of longifolicin by Marshall’s group.
Scheme 2: Total synthesis of corossoline by Tanaka’s group.
Scheme 3: Total synthesis of corossoline by Wu’s group.
Scheme 4: Total synthesis of pseudo-annonacin A by Hanessian’s group.
Scheme 5: Total synthesis of tonkinecin by Wu’s group.
Scheme 6: Total synthesis of gigantetrocin A by Shi’s group.
Scheme 7: Total synthesis of annonacin by Wu’s group.
Scheme 8: Total synthesis of solamin by Kitahara’s group.
Scheme 9: Total synthesis of solamin by Mioskowski’s group.
Scheme 10: Total synthesis of cis-solamin by Makabe’s group.
Scheme 11: Total synthesis of cis-solamin by Brown’s group.
Scheme 12: The formal synthesis of (+)-cis-solamin by Donohoe’s group.
Scheme 13: Total synthesis of cis-solamin by Stark’s group.
Scheme 14: Total synthesis of mosin B by Tanaka’s group.
Scheme 15: Total synthesis of longicin by Hanessian’s group.
Scheme 16: Total synthesis of murisolin and 16,19-cis-murisolin by Tanaka’s group.
Scheme 17: Synthesis of a stereoisomer library of (+)-murisolin by Curran’s group.
Scheme 18: Total synthesis of murisolin by Makabe’s group.
Scheme 19: Total synthesis of reticulatain-1 by Makabe’s group.
Scheme 20: Total synthesis of muricatetrocin C by Ley’s group.
Scheme 21: Total synthesis of (4R,12S,15S,16S,19R,20R,34S)-muricatetrocin (146) and (4R,12R,15S,16S,19R,20R,34S...
Scheme 22: Total synthesis of parviflorin by Hoye’s group.
Scheme 23: Total synthesis of parviflorin by Trost’s group.
Scheme 24: Total synthesis of trilobacin by Sinha’s group.
Scheme 25: Total synthesis of 15-epi-annonin I 181b by Scharf’s group.
Scheme 26: Total synthesis of squamocin A and squamocin D by Scharf’s group.
Scheme 27: Total synthesis of asiminocin by Marshall’s group.
Scheme 28: Total synthesis of asiminecin by Marshall’s group.
Scheme 29: Total synthesis of (+)-(30S)-bullanin by Marshall’s group.
Scheme 30: Total synthesis of uvaricin by the group of Sinha and Keinan.
Scheme 31: Formal synthesis of uvaricin by Burke’s group.
Scheme 32: Total synthesis of trilobin by Marshall’s group.
Scheme 33: Total synthesis of trilobin by the group of Sinha and Keinan.
Scheme 34: Total synthesis of asimilobin by the group of Wang and Shi.
Scheme 35: Total synthesis of squamotacin by the group of Sinha and Keinan.
Scheme 36: Total synthesis of asimicin by Marshall’s group.
Scheme 37: Total synthesis of asimicin by the group of Sinha and Keinan.
Scheme 38: Total synthesis of asimicin by Roush’s group.
Scheme 39: Total synthesis of asimicin by Marshall’s group.
Scheme 40: Total synthesis of 10-hydroxyasimicin by Ley’s group.
Scheme 41: Total synthesis of asimin by Marshall’s group.
Scheme 42: Total synthesis of bullatacin by the group of Sinha and Keinan.
Scheme 43: Total synthesis of bullatacin by Roush’s group.
Scheme 44: Total synthesis of bullatacin by Pagenkopf’s group.
Scheme 45: Total synthesis of rollidecins C and D by the group of Sinha and Keinan.
Scheme 46: Total synthesis of 30(S)-hydroxybullatacin by Marshall’s group.
Scheme 47: Total synthesis of uvarigrandin A and 5(R)-uvarigrandin A by Marshall’s group.
Scheme 48: Total synthesis of membranacin by Brown’s group.
Scheme 49: Total synthesis of membranacin by Lee’s group.
Scheme 50: Total synthesis of rolliniastatin 1 and rollimembrin by Lee’s group.
Scheme 51: Total synthesis of longimicin D by the group of Maezaki and Tanaka.
Scheme 52: Total synthesis of the structure proposed for mucoxin by Borhan’s group.
Scheme 53: Modular synthesis of adjacent bis-THF annonaceous acetogenins by Marshall’s group.
Scheme 54: Total synthesis of 4-deoxygigantecin by Tanaka’s group.
Scheme 55: Total synthesis of squamostatins D by Marshall’s group.
Scheme 56: Total synthesis of gigantecin by Crimmins’s group.
Scheme 57: Total synthesis of gigantecin by Hoye’s group.
Scheme 58: Total synthesis of cis-sylvaticin by Donohoe’s group.
Scheme 59: Total synthesis of 17(S),18(S)-goniocin by Sinha’s group.
Scheme 60: Total synthesis of goniocin and cyclogoniodenin T by the group of Sinha and Keinan.
Scheme 61: Total synthesis of jimenezin by Takahashi’s group.
Scheme 62: Total synthesis of jimenezin by Lee’s group.
Scheme 63: Total synthesis of jimenezin by Hoffmann’s group.
Scheme 64: Total synthesis of muconin by Jacobsen’s group.
Scheme 65: Total synthesis of (+)-muconin by Kitahara’s group.
Scheme 66: Total synthesis of muconin by Takahashi’s group.
Scheme 67: Total synthesis of muconin by the group of Yoshimitsu and Nagaoka.
Scheme 68: Total synthesis of mucocin by the group of Sinha and Keinan.
Scheme 69: Total synthesis of mucocin by Takahashi’s group.
Scheme 70: Total synthesis of (−)-mucocin by Koert’s group.
Scheme 71: Total synthesis of mucocin by the group of Takahashi and Nakata.
Scheme 72: Total synthesis of mucocin by Evans’s group.
Scheme 73: Total synthesis of mucocin by Mootoo’s group.
Scheme 74: Total synthesis of (−)-mucocin by Crimmins’s group.
Scheme 75: Total synthesis of pyranicin by the group of Takahashi and Nakata.
Scheme 76: Total synthesis of pyranicin by Rein’s group.
Scheme 77: Total synthesis of proposed pyragonicin by the group of Takahashi and Nakata.
Scheme 78: Total synthesis of pyragonicin by Rein’s group.
Scheme 79: Total synthesis of pyragonicin by Takahashi’s group.
Scheme 80: Total synthesis of squamostanal A by Figadère’s group.
Scheme 81: Total synthesis of diepomuricanin by Tanaka’s group.
Scheme 82: Total synthesis of (−)-muricatacin [(R,R)-373a] and its enantiomer (+)-muricatacin [(S,S)-373b] by ...
Scheme 83: Total synthesis of epi-muricatacin (+)-(S,R)-373c and (−)-(R,S)-373d by Scharf’s group.
Scheme 84: Total synthesis of (−)-muricatacin 373a and 5-epi-(−)-muricatacin 373d by Uang’s group.
Scheme 85: Total synthesis of four stereoisomers of muricatacin by Yoon’s group.
Scheme 86: Total synthesis of (+)-muricatacin by Figadère’s group.
Scheme 87: Total synthesis of (+)-epi-muricatacin and (−)-muricatacin by Couladouros’s group.
Scheme 88: Total synthesis of muricatacin by Trost’s group.
Scheme 89: Total synthesis of (−)-(4R,5R)-muricatacin by Heck and Mioskowski’s group.
Scheme 90: Total synthesis of muricatacin (−)-373a by the group of Carda and Marco.
Scheme 91: Total synthesis of (−)- and (+)-muricatacin by Popsavin’s group.
Scheme 92: Total synthesis of (−)-muricatacin by the group of Bernard and Piras.
Scheme 93: Total synthesis of (−)-muricatacin by the group of Yoshimitsu and Nagaoka.
Scheme 94: Total synthesis of (−)-muricatacin by Quinn’s group.
Scheme 95: Total synthesis of montecristin by Brückner’s group.
Scheme 96: Total synthesis of (−)-acaterin by the group of Franck and Figadère.
Scheme 97: Total synthesis of (−)-acaterin by Singh’s group.
Scheme 98: Total synthesis of (−)-acaterin by Kumar’s group.
Scheme 99: Total synthesis of rollicosin by Quinn’s group.
Scheme 100: Total synthesis of Rollicosin by Makabe’s group.
Scheme 101: Total synthesis of squamostolide by Makabe’s group.
Scheme 102: Total synthesis of tonkinelin by Makabe’s group.
Beilstein J. Org. Chem. 2007, 3, No. 45, doi:10.1186/1860-5397-3-45
Graphical Abstract
Figure 1: Reaction of α-acylxanthate 1a with 1-decene and Et3B/air.
Figure 2: Xanthates and thionoimidazolides 2–16 and their reduced derivatives.
Scheme 1: Reduction of xanthate 17a at different temperatures with Et3B (5 equiv.)/air.
Scheme 2: Reduction of S-alkylxanthates and O-alkylxanthates.
Scheme 3: Reduction of O-alkyl-S-methyl xanthate 19, thionoimidazolide 21 and iodide 22 by Et3B/air at 20°C.
Scheme 4: Products formed through a putative 1,5-hydrogen atom transfer.
Beilstein J. Org. Chem. 2006, 2, No. 24, doi:10.1186/1860-5397-2-24
Graphical Abstract
Figure 1: Tetramic acid antibiotics from natural sources.
Scheme 1: Synthesis of tetronolactonyl aldehydes from L-ascorbic acid
Scheme 2: Synthesis of tetronolactonyl dienyl esters from etronolactonyl aldehydes
Figure 2: H-bonding in tetronolactonyl dienyl esters.
Scheme 3: Synthesis of 5-hydroxy lactams from dienyl tetronic esters
Scheme 4: Synthesis of dienyl tetramic acid from 5- hydroxy lactams
Beilstein J. Org. Chem. 2006, 2, No. 14, doi:10.1186/1860-5397-2-14
Graphical Abstract
Scheme 1: Acetyl migration products upon TBAF/THF treatment
Scheme 2: Synthesis of riboside 1. a) 2,2-Dimethoxypropane, p-toluenesulfonic acid, acetone (65%); b) TBDMSCl...
Scheme 3: Synthesis of xyloside 2 and riboside 3. a) i) acetone, p-toluenesulfonic acid, CuSO4; ii) HCl 0.2 M...
Scheme 4: Synthesis of arabinoside 4. a) HSEt, 6M aq HCl (85%); b) TBDPSCl, imidazole, DMAP, DMF (94%); c) Hg...
Scheme 5: Synthesis of riboside 5. a) BnBr, NaH, THF (82%); b) TBAF, THF (84%); c) PivCl, pyridine/DCM, DMAP ...
Scheme 6: Alkoxide promoted transesterification.
Beilstein J. Org. Chem. 2006, 2, No. 12, doi:10.1186/1860-5397-2-12
Graphical Abstract
Figure 1: Structures of common ionic liquids.
Scheme 1: Glycosylation of 1 and 2 with various glycosyl donors.
Beilstein J. Org. Chem. 2005, 1, No. 12, doi:10.1186/1860-5397-1-12
Graphical Abstract
Figure 1: Sugars, iminosugars and carbasugars.
Figure 2: Retrosynthetic analysis.
Scheme 1: Reagents and conditions: (a) OsO4, NMO, tBuOH, rt; (b) TFA, H2O, rt.
Scheme 2: Reagents and conditions: (a) mCPBA, CH2Cl2, NaHCO3, rt; (b) see text.
Scheme 3: Reagents and conditions: (a) i : SOCl2, Et3N, CH2Cl2, 0°C; ii : RuCl3, NaIO4, CCl4, CH3CN, 0°C to r...
Figure 3: 1D proton NMR spectra of the C8 ring in compound 11 (upper) and the simulated signals (down) on the...
Figure 4: Schematic representation of the NOEs (indicated with arrows) found to deduce the structure of 11. B...
Figure 5: X-ray structure of epoxide 7 (upper) and sulfate 9 (down) solved using SHELXS and anisotropically r...
Beilstein J. Org. Chem. 2005, 1, No. 10, doi:10.1186/1860-5397-1-10
Graphical Abstract
Scheme 1:
Figure 1: Evolution of conversion of ketone 1 using PAMO mutant P3 with increasing substrate concentration in...
Scheme 2:
Figure 2: Effect of different solvents on the stability of PAMO, measured as residual activity. For cyclohexa...
Scheme 3:
Figure 3: Conversion during the oxidation of ketone 6 in a two-liquid phase system over the time. The catalys...